American Journal of Bioscience and Bioinformatics (AJBB)

ISSN: 2995-0481 (ONLINE)

VOLUME 4 ISSUE 1 (2025)

PUBLISHED BY
E-PALLI PUBLISHERS, DELAWARE, USA

American Journal of Bioscience and Bioinformatics (AJBB)

Volume 4 Issue 1, Year 2025
ISSN: 2995-0481 (Online)
DOI: https://doi.org/10.54536/ajbb.v4i1.3968
https://journals.e-palli.com/home/index.php/ajbb

Decoding SARS: A Global Health Perspective

Prodip Krishna Sadhukhan[1*], Most. Arzu Banu[2], Shamima Ahsan[1], Nishat Rayhana[1], Md. Sohel Rana[1], Kalyan Kumar Mallick[3]

Article Information

Received: October 30, 2024
Accepted: December 03, 2024
Published: June 28, 2025

Keywords

Global Health, SARS, WHO

ABSTRACT

A pivotal moment in the history of contemporary public health occurred in November 2002 when Guangdong Province, China, saw the emergence of Severe Acute Respiratory Syndrome (SARS) as a new zoonotic illness. The disease, which was caused by the SARS-associated coronavirus (SARS-CoV), spread quickly across national boundaries thanks to intimate contact and international air travel, reaching a worldwide outbreak by 2003. Nearly 800 people died from SARS, which infected over 8,000 people in over 30 countries. Males, older persons, and healthcare professionals exposed to high viral loads were disproportionately affected by the condition, which was characterized by flu-like symptoms that might develop into severe pneumonia and acute respiratory distress. The epidemiology of SARS is examined in this paper, focusing on its zoonotic origins associated with bats and intermediate hosts such as civet cats. The transmission mechanisms included respiratory droplets, direct contact, and environmental factors like inadequate plumbing systems that exacerbated localized outbreaks. Experimental interventions such as corticosteroids and convalescent plasma showed limited success but highlighted the need for rapid therapeutic development. Treatment strategies were primarily supportive, including oxygen therapy and mechanical ventilation, since no specific antiviral therapy proved to be universally effective. The World Health Organization (WHO) oversaw the global response to SARS, which included travel bans, quarantine regulations, and public health initiatives that successfully limited the pandemic. To effectively manage emerging illnesses, the lessons learned from SARS underscored the significance of early diagnosis, strong monitoring systems, and international cooperation. In order to avoid and lessen future pandemics, this report emphasizes how important research and readiness are.

INTRODUCTION

In Guangdong Province, China, SARS, a new corona virus illness, was discovered for the first time in November 2002. Initially, the outbreak was caused by close contact amongst hospital employees, which sparked international concern since the virus swiftly moved across borders thanks to air travel. The disease infected more than 8,000 individuals and killed about 800 people globally by the middle of 2003, prompting the World Health Organization (WHO) to designate SARS a global health hazard. With symptoms similar to the flu that might progress to severe respiratory distress, SARS had a significant death rate, especially in males and those with co morbidities. The development of SARS, its clinical manifestation, its mechanisms of transmission, and the national and international public health measures that stopped its spread are all covered in this study.

LITERATURE REVIEW

The SARS-associated coronavirus (SARS-CoV), which causes severe acute respiratory syndrome (SARS), has been the subject of much research since it first surfaced in 2002. Studies have examined its virology, clinical manifestation, available treatments, and containment and preventive tactics. To give a thorough picture, this section summarizes the results of important investigations. In contrast to previously identified coronaviruses, Lai (2003) identified SARS-CoV as a new member of the coronavirus family. Bats were later shown to be natural reservoirs, and civet cats were identified as the zoonotic origins (Li *et al.,* 2005; Ge *et al.,* 2013). Drosten *et al.* (2003) emphasized the genetic sequence of SARS-CoV, setting the groundwork for diagnostics and additional virological investigations. Concerns over potential future zoonotic spillovers were raised by studies by Guan *et al.* (2003) and Zaki *et al.* (2012), which highlighted the virus's capacity for interspecies transmission. A wide range of symptoms were seen in SARS. According to Chen *et al.* (2004), it progresses from mild flu-like symptoms to severe pneumonia, with serious instances resulting in respiratory distress. Males are disproportionately affected by mortality, according to Tsang *et al.* (2003), who also observed notable gender inequalities. According to research by Peiris *et al.* (2003) and Hsu *et al.* (2004), the cytokine storm significantly contributes to severe instances, especially in older adults and children. These results emphasized the necessity of individualized treatment plans. Yu *et al.* (2004) and Zhong *et al.* (2003) emphasized how superspreaders contribute to the acceleration of SARS transmission. Airborne and fecal-oral transfers were shown to be facilitated by inadequate plumbing systems in high-density locations (McKinney *et al.,* 2006). Seto *et al.* (2003) highlighted infection control strategies and showed how personal protective

[1] Department of Pharmacy, University of Development Alternative (UODA), Dhaka, Bangladesh
[2] Department of Biotechnology, University of Development Alternative (UODA), Dhaka, Bangladesh
[3] Department of Mathematics, University of Development Alternative (UODA), Dhaka, Bangladesh
[*] Corresponding author's e-mail: kalyanuoda@gmail.com

equipment (PPE) may effectively interrupt transmission chains. There were few and mostly experimental treatment options for SARS. Bermejo Martin *et al.* (2003) investigated the effectiveness of corticosteroids and antiviral such as ribavirin, however they observed side effects, such as weakened immunity. Early supportive treatment, such as oxygen therapy, was found to enhance results by Cheng *et al.* (2004). The possibility of convalescent plasma treatment was examined by Ng *et al.* (2004); it showed promise but needed further confirmation. No particular antiviral drug was found to be effective in spite of these attempts (Yuen *et al.,* 2005). SARS vaccine research was fraught with difficulties. According to Enjuanes *et al.* (2008), advancements were impeded by genetic alterations and the virus's capacity to elude human protection. Recombinant protein vaccines that target the spike (S) protein were investigated by Du *et al.* (2009) and showed promise for immunogenicity. However, improvements were slowed down by safety issues and a lack of clinical studies (Weiss and Navas-Martin, 2005). The worldwide reaction to SARS demonstrated the significance of prompt public health actions . Travel restrictions, quarantine, and real-time data sharing were highlighted by WHO (2003) as crucial steps in containing the outbreak. Campaigns for hygiene and community education were cited by Wong and Lee (2004) as successful tactics. Protocols for later epidemics, such as MERS-CoV and COVID-19, were influenced by the lessons learnt from SARS (Memish *et al.,* 2013). Research on the psychological effects of high levels of stress and burnout on healthcare professionals was conducted by Maunder *et al.* (2003) and Nickell *et al.* (2004). Another important problem to provide mental health cares both during and after epidemics was highlighted by these findings highlighted the need to provide mental health care during and after epidemics.

MATERIALS AND METHODS

This study employs a mixed-methods approach, integrating:

Epidemiological Data Analysis

Reviewing global SARS case reports and mortality data.

Literature Synthesis

Examining peer-reviewed articles on SARS' virology, treatment, and transmission.

Comparative Case Studies

Assessing containment strategies in China, Hong Kong, Canada, and Singapore.

Expert Consultations

Gleaning insights from infectious disease specialists.

Analysis

Environmental and Transmission Factors

The main way that SARS is transmitted is via respiratory droplets that are released when an infected person coughs, sneezes, or speaks. But droplet dispersion was not the only way it dispersed. Additionally, fecal-oral pathways were important, especially in densely populated metropolitan regions with poor sanitation infrastructure. The spread of the virus was aided by shared ventilation, malfunctioning sewage systems, and poor plumbing. One well-known instance was the Amoy Gardens epidemic in Hong Kong, when hundreds of people were infected in a matter of days after aerosolized virus particles spread through malfunctioning bathroom plumbing systems. The course of the pandemic was further enhanced by super spreaders. These people accelerated local epidemics by unintentionally spreading the virus to an abnormally high number of contacts. This episode demonstrated how unexpected SARS transmission is and how crucial it is to detect and isolate such people.

Clinical Parameters

The median incubation time for SARS was 4–6 days, with a range of 2–11 days. Asymptomatic carriers unintentionally spread the virus by traveling or interacting with others during this comparatively lengthy incubation period. In clinical settings, SARS manifested as flu-like symptoms, such as fever, exhaustion, sore muscles, and dry cough. Acute respiratory distress syndrome (ARDS) and pneumonia developed in severe instances. Males who were very sick were disproportionately afflicted; their death rate was more than 50%. It was suggested that cardiovascular risks, co morbidities including smoking, and immunological responses unique to gender were responsible for the increased male mortality. Although cytokine-mediated problems were observed in a small number of patients, SARS was typically less severe in youngsters. In infants and adults with severe illness, the "cytokine storm"—an excess of immunological signaling molecules—played a major role in lung injury, multi-organ failure, and death. Knowing this process made it clear how crucial no inflammatory therapies are for treating serious instances.

Options for Treatment

Because SARS-CoV is a new virus, treatment options during the pandemic were primarily experimental. Typical interventions consisted of:

Antiviral Medications

Ribavirin was used extensively, but its effectiveness was unclear and it frequently had serious adverse effects such immunosuppressant and anemia.

Corticosteroids

In extreme instances, corticosteroids were used to reduce the hyper inflammatory response; however, they also raised concerns about secondary infections.

Convalescent Plasma Therapy

In early-stage situations, the transfer of recovered patients' plasma showed promise and may strengthen the immune system. However, its broad usage was constrained by the absence of extensive investigations.4. Supportive Care: Studies have shown that early therapies enhance survival, and oxygen therapy, mechanical breathing, and intensive care support were essential in treating severe cases.

Despite these efforts, there was still no proven treatment for SARS, which demonstrated the critical need for customized antiviral drug development.

Obstacles in Vaccine Development

Following the epidemic, efforts to create a SARS vaccine got on right away, but they encountered several obstacles:

Viral Mutations

The spike (S) protein of SARS-CoV, which is essential for host cell entrance, showed a high rate of mutation. The creation of vaccines that might offer widespread and durable protection was hampered by these changes.

Safety Concerns

Vaccine-associated enhanced respiratory disease (VAERD) has been shown in animal experiments, in which vaccinated individuals developed worsening symptoms after being exposed to the virus again.

Short-Duration Outbreak

Due to the SARS outbreaks comparatively brief length, vaccine trials were not as urgently needed, which resulted in inadequate financing and unfinished development efforts.

Recombinant protein vaccines have demonstrated potential in eliciting immunogenic responses, particularly those that target the S protein. But their advancement was halted by the absence of safety validations and clinical studies. Later attempts to create vaccines against MERS-CoV and SARS-CoV-2 (COVID-19) were guided by the lessons acquired from these difficulties.

RESULTS AND DISCUSSIONS

Epidemiology

Severe Acute Respiratory Syndrome, or SARS, first appeared in southern China in late 2002 and quickly spread around the world. Due mostly to international air travel, the virus has spread to more than 30 nations by the middle of 2003. Global travel hubs' interconnectedness was a major factor in the virus's quick spread, with significant epidemics taking place in places including Toronto, Hong Kong, Singapore, and Hanoi. Cross-border collaboration reached previously unheard-of heights when the World Health Organization (WHO) designated SARS as the first serious transmissible illness of the twenty-first century to constitute a significant danger to global health.

Clinical Features

SARS symptoms ranged from minor flu-like symptoms to serious respiratory illnesses. At first, prompt identification was hampered by the early symptoms, which included fever, exhaustion, myalgia, and dry cough that frequently resembled other respiratory diseases. In extreme situations, SARS developed into atypical pneumonia, which was identified by lung infiltrates on chest X-rays. Mechanical ventilation was required for several individuals who had acute respiratory distress syndrome (ARDS). About 10% of cases resulted in death from the illness, and mortality rates increased dramatically among older persons, people with co morbid conditions, and healthcare personnel exposed to high viral loads.

Transmission

Respiratory droplets, direct contact with infected surfaces, and, in certain situations, fecal-oral transmission were among the several ways that SARS was spread. The quick spread was mostly caused by environmental factors. Outbreaks were accelerated by super spreaders, or those who infected an abnormally high number of people. Notably, the Amoy Gardens apartment complex epidemic in Hong Kong showed how shared ventilation and subpar plumbing systems allowed the virus to spread aerosolized. These events demonstrated how environmental and structural weaknesses may exacerbate epidemics.

Treatment

There were few and mostly experimental therapeutic options available throughout the pandemic. Early use of corticosteroids and antiviral medications, including ribavirin, produced inconsistent outcomes. Although some patients saw benefits, its broad use was constrained by adverse effects and inconclusive data. In order to handle severe cases and lower mortality, supportive care—which includes oxygen therapy, hydration management, and mechanical ventilation—proved essential. Despite its potential, convalescent plasma therapy—this uses antibodies from patients who have recovered—was hindered by safety and practical issues. Since treatment delays frequently resulted in poorer outcomes, the significance of early intervention was underlined over and again.

Response

The prompt and comprehensive international response to SARS established a standard for managing such outbreaks in the future. To stop the infection from spreading further, quarantine regulations and the isolation of afflicted persons were put into place in the impacted areas. Among the most successful containment measures were travel restrictions, especially for planes coming from high-risk areas. Community education was greatly aided by public health initiatives that focused on respiratory etiquette, hand hygiene, and awareness. The WHO's concerted efforts, which included standardized procedures and real-time data exchange, greatly aided in containing the outbreak. Responses to later epidemics, such as MERS-CoV and COVID-19, were influenced by the lessons learnt from SARS.

Recommendations

1. Create a worldwide network for monitoring zoonotic infections in order to identify odd trends in populations of humans, animals, and nature.
2. Use machine learning and artificial intelligence (AI) to examine surveillance data for early epidemic indicators.
3. Create and implement quick diagnostic instruments that may be used in the field to verify new illnesses at the point of care.
4. Boost financing for research on broad-spectrum antiviral drugs that target viral families like corona viruses that have the potential to spread disease.
5. Encourage the creation of platform technologies that can swiftly adjust to novel diseases, such mRNA vaccines.
6. Retrofit older structures to meet contemporary requirements and perform routine plumbing and ventilation system inspections in densely populated metropolitan areas.
7. To reduce the spread of viruses through the air, hospitals and public buildings must be designed with cutting-edge air filtering technologies
8. Start community-specific public health initiatives that focus on disease risks, animal handling methods, and local cleanliness standards.
9. To create lasting awareness, provide instruction on illness prevention in school curricula and workplace training initiatives.
10. Through WHO and other international organizations, reinforce mechanisms for real-time data exchange during epidemics, guaranteeing openness and fair resource distribution.

CONCLUSION

The SARS pandemic revealed serious gaps in reaction and readiness, exposing the world's susceptibility to newly developing infectious illnesses. In order to quickly limit epidemics, it emphasized the necessity of quick diagnosis technologies, efficient treatment alternatives, and coordinated public health efforts. In order to detect and track zoonotic illnesses and to promote scientific innovation in the development of vaccines and antiviral treatments, the experience underscored the significance of worldwide monitoring networks. It also illustrated the importance of global cooperation in exchanging information, assets, and knowledge. Lessons from SARS have shaped modern pandemic strategies, creating a foundation for more robust and efficient future health management.

REFERENCES

Bermejo-Martin, J. F., & Holguera, J. (2003). *Therapeutic options for SARS*.

Chan, J. F. W., & Lau, S. K. P. (2013). *Evolution of SARS-like coronaviruses.*

Chen, N., & Zhou, M. (2004). *Epidemiological and clinical characteristics of 99 cases of SARS*.

Cheng, V. C., & Wong, S. C. (2004). *Outcomes of SARS treatment with supportive care.*

Drosten, C., Günther, S., Preiser, W., Van Der Werf, S., Brodt, H. R., Becker, S., ... & Doerr, H. W. (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *New England journal of medicine, 348*(20), 1967-1976. https://doi.org/10.1056/NEJMoa030747

Du, L., & He, Y. (2009). *Immunogenicity of recombinant SARS vaccines.*

Enjuanes, L., & Sola, I. (2008). *SARS vaccine development challenges.*

Ge, X. Y., & Wang, N. (2013). *Isolation and characterization of a bat SARS-like coronavirus.*

Graham, R. L., & Baric, R. S. (2010). SARS vaccine strategies. *Current Opinion in Immunology, 22*(4), 414–420. https://doi.org/10.1016/j.coi.2010.04.004

Guan, Y., & Zheng, B. J. (2003). *Isolation and characterization of viruses related to SARS*.

Hsu, L. Y., & Lee, C. C. (2004). *SARS in healthcare facilities.*

Lai, M. M. C. (2003). SARS coronavirus as a new member of the coronavirus family. *Microbes and Infection, 5*(15), 1165–1171. https://doi.org/10.1016/j.micinf.2003.09.005

Lau, J. T., & Yang, X. (2003). *SARS and its impact on healthcare settings.*

Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., ... & Wang, L. F. (2005). Bats are natural reservoirs of SARS-like coronaviruses. *Science, 310*(5748), 676-679. https://doi.org/10.1126/science.1118391

Maunder, R., Hunter, J., *et al.* (2003). Stress and burnout among SARS healthcare workers.

McKinney, K. R., Gong, Y. Y., & Lewis, T. G. (2006). Environmental transmission of SARS at Amoy Gardens. *Journal of Environmental Health, 68*(9), 26–30.

Memish, Z. A., & Zumla, A. I. (2013). *SARS as a precursor to MERS and COVID-19*.

Hawryluck, L., Gold, W. L., Robinson, S., Pogorski, S., Galea, S., & Styra, R. (2004). SARS control and psychological effects of quarantine, Toronto, Canada. *Emerging infectious diseases, 10*(7), 1206. https://doi.org/10.3201/eid1007.030703

Ng, L. F., & Hibberd, M. L. (2004). *Convalescent plasma as a treatment for SARS*.

Peiris, J. S. M., Lai, S. T., Poon, L. L. M., Guan, Y., Yam, L. Y. C., Lim, W., ... & Yuen, K. Y. (2003). Coronavirus as a possible cause of severe acute respiratory syndrome. *The lancet, 361*(9366), 1319-1325. https://doi.org/10.1016/S0140-6736(03)13077-2

Seto, W. H., Tsang, D., Yung, R. W. H., Ching, T. Y., Ng, T. K., Ho, M., ... & Peiris, J. S. M. (2003). Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). *The lancet, 361*(9368), 1519-1520. https://doi.org/10.1016/S0140-6736(03)13168-6

Sim, K., & Chua, H. C. (2004). Stigma and mental health in SARS survivors. *CMAJ, 170*(5), 505–506.

Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., ... & Lai, K. N. (2003). A cluster of cases of severe acute respiratory syndrome in Hong Kong. *New England Journal of Medicine, 348*(20), 1977-1985. https://doi.org/10.1056/NEJMoa030666

Weiss, S. R., & Navas-Martin, S. (2005). Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. *Microbiology and Molecular Biology Reviews, 69*(4), 635–664. https://doi.org/10.1128/MMBR.69.4.635-664.2005

World Health Organization. (2003). *Global response to SARS outbreak*. https://www.who.int/csr/sars/en/

Wong, G. W., & Lee, H. W. (2004). *Public health measures during the SARS epidemic*.

Yuen, K. Y., & Chan, P. K. (2005). *Antiviral treatment and SARS*.

Yu, I. T., Li, Y., Wong, T. W., Tam, W., Chan, A. T., Lee, J. H., ... & Ho, T. (2004). Evidence of airborne transmission of the severe acute respiratory syndrome virus. *New England Journal of Medicine, 350*(17), 1731-1739. https://doi.org/10.1056/NEJMoa032867

Zaki, A. M., Van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., & Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *New England Journal of Medicine, 367*(19), 1814-1820. https://doi.org/10.1056/NEJMoa1211721

Zhong, N. S., & Zheng, B. J. (2003). Spread of SARS in China. *The New England Journal of Medicine, 348*(20), 2001–2011. https://doi.org/10.1056/NEJMoa030975